报价延迟最少15分钟:2026/03/29 20:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.53 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.83/-0.22
|
|
企业价值
769.53M
|
| 资产负债 |
|
每股账面净值
15.84
|
| 现金流量 |
|
现金流量率
0.09
|
| 损益表 |
|
收益
344.23M
|
|
每股收益
6.46
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests. |
